Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
More News related to ONXX
- Onyx Pharmaceuticals Announces December 2009 Investor Events
- Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX
- Onyx Pharmaceuticals (ONXX) Completes Acquisition of Proteolix
- Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
More News related to New Coverage
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
Craig-Hallum initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Buy. Price target $35.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
